Building the world’s leading endemic resilience platform.
Adagio is developing best-in-class antibodies that can broadly neutralize targeted families of viruses. The company is currently targeting SARS-CoV-2, SARS-CoV-1 and additional potentially emergent coronaviruses. Adagio antibodies will match or exceed the potency and coverage of conventional SARS-CoV-2 antibody programs, and can be used as both therapeutic and durable prophylactic treatments. As the ongoing COVID-19 pandemic evolves into a multi-variant endemic, Adagio’s portfolio of multiple, non-competing antibodies with distinct binding targets enables a durable response strategy that can avoid viral escape.